Loading...
•
Dec 31, 2020
Akero Q4 2020 Earnings Report
Akero Therapeutics reported fourth quarter and full year financial results for the period ending December 31, 2020.
Key Takeaways
Akero Therapeutics reported results from its Phase 2a BALANCED study in biopsy-confirmed NASH patients, suggesting that efruxifermin (EFX) has the potential to be a foundational monotherapy for treatment of NASH.
Reported strong results from Phase 2a BALANCED study in NASH patients.
Observed rapid improvements in both fibrosis and NASH resolution in biopsy data.
Planning to report additional biopsy data among cirrhotic patients by April.
Provided updates on Phase 2b HARMONY study and regulatory and manufacturing updates.
Akero
Akero
Forward Guidance
Akero is developing transformational treatments for non-alcoholic steatohepatitis (NASH).